Abstract 168P
Background
Routine genomic profiling in metastasic solid tumors has an impact on survival by selecting targeted therapies and montoring treatment response. Moreover, feasibility and efficiency of liquid biopsy (LB) in pancreatic cancer has been studied as tissue is not always available in these tumors given the frequent lack of tissue in these tumors.
Methods
We present an ambispective observational study in patients with locally advanced or metastatic pancreatic cancer who underwent LB before starting chemotherapy. The primary end point was to determine the prevalence of pathological molecular alterations in circulating tumor DNA (ctDNA) and their concordance with next generation sequencing in tumor tissue (TNGS). A secondary end point was the study of circulating tumor cells (CTCs) as a poor prognostic factor for survival.
Results
A total of 30 patients were included between May 2020 and September 2022. Women were 53.3% of them, and the median age was 65.5 years (37-85). At the time of LB, 86.7% had metastatic disease, 6.7% had stage III, and 6.7% had stage II. 83.4% were about to initiate a first-line chemotherapy. 86.7% of the patients had also undergone TNGS. In both LB and TNGS, one or more molecular alterations were found in 80% of patients. Fourteen different molecular alterations were found in LB, with the most prevalent mutations in TP53 (56.6%), KRAS (53.3%), ERBB2 (16.6%), MET (4%), and EGFR (4%). In TNGS, 12 alterations were found, with the most prevalent being TP53 (46.6%), KRAS (60%), MET (23.3%), and EGFR (13.3%). The concordance rate between BL and TNGS was > 70%. The median overall survival (OS) was 5.5 months (95%CI:3.6-7.4). In patients without CTCs, the OS was 6.3 months (95%CI:4.7-8.0), while patients with CTCs had an OS of 3.6 months (95%CI:1.6-5.6).
Conclusions
80% of patients presented molecular alterations in both LB and TNGS with a matching rate > 70%. The most prevalent mutations were TP53, KRAS, MET, EGFR and ERBBE in the two analyses. The presence of CTCs is a poor prognostic factor.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
93P - A new platform for fast-track molecular stratification of endometrial carcinomas enabling timely treatment decisions in precision oncology
Presenter: Susanne Walz
Session: Cocktail & Poster Display session
Resources:
Abstract
94P - Harnessing circulating tumor DNA in bronchoalveolar lavage fluid for precise molecular diagnosis of NSCLC
Presenter: Frank Borm
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Automatic data processing to identify EGFR mutations in pathology reports of patients with non-small cell lung cancer (NSCLC)
Presenter: Betzabel Cajiao Garcia
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in endometrial cancer (EC) patients
Presenter: Simona Duranti
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Prospects of liquid biopsy in determining prognosis in children with HGG and DIPG
Presenter: Olga Regentova
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Liquid biopsy in NSCLC: A promising tool to predict immunotherapy response
Presenter: Ana Fernández
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Comprehensive genomic sequencing as an ancillary diagnostic tool for pathologists
Presenter: Dan Miller
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Standard serum biomarkers to help predict a cancer diagnosis in patients with non-specific symptoms: Data from Guy´s rapid diagnostic clinic
Presenter: Maria Monroy Iglesias
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Patient-derived organoids to optimize CDK4/6 inhibitor-based treatment selection in early breast cancer
Presenter: Carla Alves
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - MicroRNAs in urine and saliva as non-invasive biomarkers of minimal residual disease in pediatric acute lymphoblastic leukemia
Presenter: Alejandra Pando-Caciano
Session: Cocktail & Poster Display session
Resources:
Abstract